Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jun 14:6:80.
doi: 10.1186/1475-2875-6-80.

Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal

Babacar Faye  1 , Jean-Louis Ndiaye, Daouda Ndiaye, Yemou Dieng, Oumar Faye, Oumar Gaye
Affiliations
Randomized Controlled Trial

Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal

Babacar Faye et al. Malar J. .

Abstract

Background: In view of the high level of chloroquine resistance in many countries, WHO has recommended the use of combination therapy with artemisinin derivatives in the treatment of uncomplicated malaria due to Plasmodium falciparum. Four antimalarial drug combinations, artesunate plus amodiaquine (Arsucam), artesunate plus mefloquine (Artequin), artemether plus lumefantrine (Coartem; four doses and six doses), and amodiaquine plus sulphadoxine-pyrimethamine, were studied in five health districts in Senegal.

Methods: This is a descriptive, analytical, open, randomized study to evaluate the efficacy and tolerability of these four antimalarial combinations in the treatment of uncomplicated falciparum malaria using the 2002 WHO protocol.

Results: All drug combinations demonstrated good efficacy. On day 28, all combinations resulted in an excellent clinical and parasitological response rate of 100% after correction for PCR results, except for the four-dose artemether-lumefantrine regimen (96.4%). Follow-up of approximately 10% of each treatment group on day 42 demonstrated an efficacy of 100%.The combinations were well tolerated clinically and biologically. No unexpected side-effect was observed and all side-effects disappeared at the end of treatment. No serious side-effect requiring premature termination of treatment was observed.

Conclusion: The four combinations are effective and well-tolerated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Parasitic clearance with the five antimalarial drug combinations.
Figure 2
Figure 2
Genotyping of resistant strains isolated from patients treated with the different antimalarial drug combinations.
See this image and copyright information in PMC

References

    1. Ministère de la Santé. Programme National de Lutte contre le Paludisme. 2001. Plan stratégique pour faire reculer le paludisme au Sénégal 2001–2005. Janvier. 2001.
    1. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001;358:368–374. doi: 10.1016/S0140-6736(01)05557-X. - DOI - PubMed
    1. Talisuna AO, Nalunkuma-Kazibwe A, Bakyaita N, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, D'Alessandro U, Egwang G. Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. Trop Med Int. 2004;9:222–229. doi: 10.1046/j.1365-3156.2003.01187.x. - DOI - PubMed
    1. OMS/WHO Les combinaisons thérapeutiques d'antipaludiques. Rapport d'une consultation technique. WHO/CDS/RBM/200135.
    1. OMS/WHO Monitoring antimalarial drug resistance. CS/CSR/EPH/200217.

Publication types

MeSH terms

LinkOut - more resources